Agilent Technologies (NYSE:A) Director Mikael Dolsten Sells 634 Shares of Stock

Agilent Technologies, Inc. (NYSE:A) Director Mikael Dolsten sold 634 shares of Agilent Technologies stock in a transaction on Friday, September 4th. The stock was sold at an average price of $151.38, for a total transaction of $95,974.92. Following the completion of the transaction, the director directly owned 4,924 shares of the company’s stock, valued at approximately $745,395.12. This represents a 11.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Agilent Technologies Stock Down 1.4%

Shares of NYSE:A opened at $144.79 on Thursday. The stock has a market capitalization of $40.82 billion, a price-to-earnings ratio of 28.50, a price-to-earnings-growth ratio of 2.24 and a beta of 1.24. Agilent Technologies, Inc. has a 1-year low of $108.35 and a 1-year high of $163.75. The company’s fifty day moving average is $143.14 and its two-hundred day moving average is $128.35. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.56 and a current ratio of 2.05.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Wednesday, August 26th. The medical research company reported $1.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.13. Agilent Technologies had a net margin of 19.53% and a return on equity of 24.45%. The business had revenue of $1.88 billion during the quarter, compared to the consensus estimate of $1.84 billion. During the same quarter in the prior year, the firm earned $1.37 EPS. The company’s revenue for the quarter was up 8.1% compared to the same quarter last year. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. Equities analysts anticipate that Agilent Technologies, Inc. will post 6.2 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Wells Fargo & Company reduced their price objective on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a research report on Thursday, May 28th. Jefferies Financial Group assumed coverage on shares of Agilent Technologies in a report on Thursday, July 9th. They set a “hold” rating and a $135.00 price target for the company. Wolfe Research reaffirmed a “hold” rating on shares of Agilent Technologies in a report on Tuesday, June 2nd. Piper Sandler initiated coverage on shares of Agilent Technologies in a research report on Thursday, June 11th. They issued a “neutral” rating and a $150.00 price objective on the stock. Finally, Royal Bank Of Canada boosted their target price on shares of Agilent Technologies from $155.00 to $185.00 and gave the company an “outperform” rating in a research note on Thursday, August 27th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $170.33.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System boosted its stake in Agilent Technologies by 12,343.3% during the 2nd quarter. California State Teachers Retirement System now owns 54,577,058 shares of the medical research company’s stock valued at $7,249,471,000 after purchasing an additional 54,138,451 shares in the last quarter. State Street Corp lifted its holdings in shares of Agilent Technologies by 1.9% in the fourth quarter. State Street Corp now owns 12,681,792 shares of the medical research company’s stock valued at $1,725,611,000 after buying an additional 241,029 shares during the period. Wellington Management Group LLP boosted its stake in Agilent Technologies by 2.7% during the second quarter. Wellington Management Group LLP now owns 7,454,686 shares of the medical research company’s stock valued at $990,206,000 after buying an additional 198,253 shares in the last quarter. Geode Capital Management LLC boosted its stake in Agilent Technologies by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 7,425,861 shares of the medical research company’s stock valued at $1,006,519,000 after buying an additional 25,139 shares in the last quarter. Finally, Deutsche Bank AG grew its holdings in Agilent Technologies by 17.1% during the second quarter. Deutsche Bank AG now owns 7,008,634 shares of the medical research company’s stock worth $930,957,000 after acquiring an additional 1,024,516 shares during the period.

About Agilent Technologies

Agilent Technologies, Inc is a global provider of analytical instruments, laboratory software, consumables and services used by organizations in the life sciences, diagnostics, pharmaceutical, chemical, environmental and food industries. Its solutions help customers analyze the composition and quality of substances, develop and manufacture products, and conduct research and testing.

The company’s offerings include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy and atomic analysis equipment, automated electrophoresis systems, laboratory informatics software, columns and other consumables.